# US 2021/0275697 A1 · Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275697 A1
- Document ID: US20210275697A1
- Status: Published application
- Kind: A1
- Application number: 17/325,258
- Filed: 2021-05-20
- Published: 2021-09-09
- Earliest claimed: 2014-08-29
- Assignees: Anmi S.A.
- Applicants: Anmi S.A.
- Inventors: Ludovic Wouters; Geoffroy Kaisin; André Luxen; Marc Léonard; Samuel Voccia
- Web page: https://patentgrep.com/patent/US20210275697A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- C07B 59/008: {Peptides; Proteins}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates the use of metal inhibitor in radiolabelling reactions using radioactive metals.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

A method for radiolabelling a chelate-functionalized targeting agent for use in in-vivo PET imaging with a metal radionuclide, comprising the steps of:
a) providing a chelate-functionalized targeting agent, able to chelate the metal radionuclide in a radiolabelling reaction, wherein the chelate functional group of the chelate-functionalized targeting agent is selected from the group consisting of DOTA, NOTA, NODAGA, HBED, DFO, EDTA, 6SS, B6SS, PLED, TAME, YM103 and H2dedpa;
b) adding a metal inhibitor not chemically linked to said chelate-functionalized targeting agent, to the radiolabelling reaction obtained in a), said metal inhibitor being a co-chelating agent selected from the group consisting of: beta-cyclodextrin, a disaccharide and a monosaccharide, capable of inactivating metals other than metal radionuclides without interfering with the chelation between the metal radionuclide and the chelate-functionalized targeting agent, under the conditions of the radiolabelling reaction, thereby obtaining a mixture of the chelate-functionalized targeting agent of a) and the metal inhibitor of b) which are not chemically linked to each other when present in said mixture; and
c) adding a metal radionuclide that is an isotope of a metal selected from the group consisting of copper, gallium, lutetium, indium, scandium, and zirconium to the mixture of a) and b) in an acetate buffer allowing to maintain the pH in the range 3-7;
wherein the targeting agent of said chelate-functionalized targeting agent is selected from the group consisting of a peptide, a peptide comprising 2 to 20 amino acids, a polypeptide, an antibody, a nanobody, a diabody, an antibody fragment, a nucleic acid, an aptamer, an antisense oligonucleotide, and an organic molecule.

### Claim 41 (depends on 40)

The method according to claim 40, wherein said metal inhibitor is present in micromolar amounts.

### Claim 42 (depends on 40)

The method according to claim 40, wherein the radiolabelling reaction is carried out at a temperature of below 50° C.

### Claim 43 (depends on 40)

The method according to claim 40, wherein the radiolabelling reaction is performed at a pH between 3 and 7.

### Claim 44 (depends on 40)

The method according to claim 40, wherein the metal radionuclide is selected from the group consisting of copper-64, gallium-68, gallium-67, gallium-66, lutetium-177, indium-114, indium-111, scandium-47, scandium-44, scandium-43, and zirconium-89.

### Claim 45 (depends on 40)

The method according to claim 40, wherein the monosaccharide is selected from the group consisting of: Glucose, Fructose, and D-Mannose.

### Claim 46

A kit for radiolabelling of a chelate-functionalized targeting agent for use in in-vivo PET imaging comprising:
a chelate-functionalized targeting agent, able to chelate a metal radionuclide in a radiolabelling reaction, wherein the chelate-functional group of the chelate-functionalized targeting agent is selected from the group consisting of DOTA, NOTA, NODAGA, HBED, DFO, EDTA, 6SS, B6SS, PLED, TAME, YM103 and H2dedpa;
a metal inhibitor, which is not chemically linked to said chelate-functionalized targeting agent and which is a co-chelating agent selected from the group consisting of beta-cyclodextrin, a disaccharide and a monosaccharide, capable of inactivating metals other than metal radionuclides without interfering with the chelation between the metal radionuclide and the chelate-functionalized targeting agent, under the conditions of the radiolabelling reaction;
a metal radionuclide that is an isotope of a metal selected from the group consisting of copper, gallium, lutetium, indium, scandium, and zirconium; and
an acetate buffer, allowing to maintain the pH in the range 3-7,
wherein the targeting agent of said chelate-functionalized targeting agent is selected from the group consisting of a peptide, a peptide comprising 2 to 20 amino acids, a polypeptide, an antibody, a nanobody, a diabody, an antibody fragment, a nucleic acid, an aptamer, an antisense oligonucleotide, and an organic molecule.

### Claim 47 (depends on 46)

The kit according to claim 46, wherein said metal inhibitor is present in micromolar amounts.

### Claim 48 (depends on 46)

The kit according to claim 46, wherein the metal radionuclide is selected from the group consisting of copper-64, gallium-68, gallium-67, gallium-66, lutetium-177, indium-114, indium-111, scandium-47, scandium-44, scandium-43, and zirconium-89.

### Claim 49 (depends on 46)

The kit according to claim 46, wherein the monosaccharide is selected from the group consisting of Glucose, Fructose, and D-Mannose.

### Claim 50 (depends on 46)

The kit according to claim 46, wherein said chelate-functionalized targeting agent and metal inhibitor are lyophilised.

### Claim 51 (depends on 40)

An in vivo method for imaging a subject comprising the steps of:
1) producing a radiolabelled chelate-functionalized targeting agent using the method of claim 40;
2) administering said radiolabelled chelate-functionalized targeting agent to the subject; and
3) detecting said radiolabelled chelate-functionalized targeting agent in the subject using positron emission tomography (PET).
